Journal
JOURNAL OF NEUROSCIENCE METHODS
Volume 303, Issue -, Pages 30-40Publisher
ELSEVIER
DOI: 10.1016/j.jneumeth.2018.03.006
Keywords
Intranasal; Parkinson's disease; Peptide; Drug delivery
Categories
Funding
- NINDS [NS039787, NS060924]
- NCATS [UL1TR000117]
- NIA [AG013494, T32-AG000242]
- Kentucky INBRE [NCRR 5P20RR016481-12, NIGMS 8P20GM103436-12]
- NIH COBRE [NCRR P20RR20171]
- Dupree Trust
- Estate of Laura C. Miller
- PhRMA Foundation
- Columbus Foundation
Ask authors/readers for more resources
Background: To determine if the intranasal delivery of neuroactive compounds is a viable, long-term treatment strategy for progressive, chronic neurodegenerative disorders, such as Parkinson's disease (PD), intranasal methodologies in preclinical models comparable to humans are needed. New method: We developed a methodology to evaluate the repeated intranasal delivery of neuroactive compounds on the non-human primate (NHP) brain, without the need for sedation. We evaluated the effects of the neuroactive peptide, DNSP-11 following repeated intranasal delivery and dose-escalation over the course of 10-weeks in Rhesus macaques. This approach allowed us to examine striatal target engagement, safety and tolerability, and brain distribution following a single (125)l-labeled DNSP-11 dose. Results: Our initial data support that repeated intranasal delivery and dose-escalation of DNSP-11 resulted in bilateral, striatal target engagement based on neurochemical changes in dopamine (DA) metabolites-without observable, adverse behavioral effects or weight loss in NHPs. Furthermore, a (125)l-labeled DNSP11 study illustrates diffuse rostral to caudal distribution in the brain including the striatum-our target region of interest. Comparison with existing methods: The results of this study are compared to our experiments in normal and 6-OHDA lesioned rats, where DNSP-11 was repeatedly delivered intranasally using a micropipette with animals under light sedation. Conclusions: The results from this proof-of-concept study support the utility of our repeated intranasal dosing methodology in awake Rhesus macaques, to evaluate the effects of neuroactive compounds on the NHP brain. Additionally, results indicate that DNSP-11 can be safely and effectively delivered intranasally in MPTP-treated NHPs, while engaging the DA system. (C) 2018 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available